Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Monoamine oxidase inhibitor-responsive depression

E Giller, D Bialos, M Riddle

    Psychiatry Research
    |February 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Abstracts of presentations to the Annual Meetings of the Canadian Association of General Surgeons Canadian Association of Thoracic Surgeons Canadian Hepato-Pancreato-Biliary Society Canadian Society of Surgical Oncology Canadian Society of Colon and Rectal Surgeons: Victoria, BC Sept. 10-13, 2009.

    Canadian journal of surgery. Journal canadien de chirurgie·2022
    Same author

    Fasting plasma glucose 6-12 weeks after starting insulin glargine predicts likelihood of treatment success: a pooled analysis.

    Diabetic medicine : a journal of the British Diabetic Association·2012
    Same author

    Snorc is a novel cartilage specific small membrane proteoglycan expressed in differentiating and articular chondrocytes.

    Osteoarthritis and cartilage·2011
    Same author

    The international study of insulin and cancer.

    Lancet (London, England)·2010
    Same author

    Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study.

    Diabetologia·2009
    Same author

    A screen of SLC1A1 for OCD-related alleles.

    American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics·2009

    This study found that the monoamine oxidase (MAO) inhibitor isocarboxazid significantly improved depression symptoms in male outpatients within six weeks. Marked improvement was linked to baseline psychomotor retardation and specific symptom changes over time.

    Area of Science:

    • Psychiatry
    • Pharmacology

    Background:

    • Monoamine oxidase (MAO) inhibitors are effective for some depression cases.
    • Isocarboxazid is an MAO inhibitor with documented efficacy.

    Purpose of the Study:

    • To evaluate the time course of platelet MAO inhibition and treatment response with isocarboxazid.
    • To identify symptoms distinguishing responders with different levels of improvement.

    Main Methods:

    • A 6-week, double-blind, placebo-controlled study involving 30 male outpatients.
    • Patients received isocarboxazid or placebo, with dosage adjusted for 90% platelet MAO inhibition.
    • Weekly assessments tracked symptom changes and side effects.

    Main Results:

    • 92% of patients on isocarboxazid improved compared to 27% on placebo.

    Related Experiment Videos

  • Symptomatic improvement was observed by week 3 in the active treatment group.
  • Anxiety improved first, followed by depression and cognitive outlook.

    • Conclusions:

    • Isocarboxazid demonstrates significant efficacy in treating depression with a favorable side effect profile.
    • Psychomotor retardation at baseline predicted greater improvement.
    • Symptom improvement followed a distinct temporal pattern.